Please login to the form below

Not currently logged in
Email:
Password:

Apeiron Biologics

This page shows the latest Apeiron Biologics news and features for those working in and with pharma, biotech and healthcare.

Keytruda and Opdivo backed for new uses in Europe

Keytruda and Opdivo backed for new uses in Europe

Apeiron Biologics also got the go-ahead for Dinutuximab beta as a treatment for high-risk neuroblastoma, an orphan indication.

Latest news

  • Sanofi and Novartis snap up immuno-oncology candidates Sanofi and Novartis snap up immuno-oncology candidates

    BioNtech - signed last year alongside smaller deals with Selecta, Evotec and Apeiron Biologics.

  • Sanofi and Evotec to work together on diabetes and cancer Sanofi and Evotec to work together on diabetes and cancer

    injections. Meanwhile, the two companies have also agreed to work together with Apeiron Biologics on novel, small-molecule immuno-oncology therapies. ... Sanofi will support two years of research funding for Evotec and Apeiron and could potentially yield

  • Advancing acquisitions

    The exception is if the company is buying into a whole new therapeutic area, platform technology or capability, such as biologics. ... Apeiron Biologics AG/GSK. APN01 - recombinant human angiotensin converting enzyme 2 (rhACE2) in ARDS.

  • GSK enters licensing deal for ARDS enzyme

    Apeiron Biologics has granted GlaxoSmithKline(GSK) exclusive rights to the Austrian company's APN01 enzyme, currently in phase I development to treat Acute Respiratory Distress Syndrome (ARDS). ... The deal will see GSK pay Apeiron an up-front payment of

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    Immunology deals. In addition to this and in keeping with the industry fashion, Sanofi has ventured into immuno-oncology with Evotec / Apeiron Biologics. ... Acquisition ‐  company. 300. Aperion Biologics Evotec. Sanofi. To develops mall molecule

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Apeiron bolsters management board Apeiron bolsters management board

    Peter Llewellyn-Davies joins as its CFO and CBO. Viennese cancer-immunotherapy focused group Apeiron Biologics has appointed a new chief financial officer and chief business officer in the form of ... He said: “Apeiron is currently amongst the most

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics